-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：ETN第一季銷售額創歷史新高，達75億美元（年增17%），有機成長率達10%，超出先前5-7%的預期範圍；營運每股收益達到創紀錄的2.81美元（年成長3%），高於市場普遍預期的2.73美元。儘管併購和產能投資給利潤率帶來壓力，但ETN的營運執行力依然強勁。我們認為，ETN斥資110億美元進行的策略性收購，包括收購Boyd Thermal（96億美元）和Ultra PCS（15億美元），將進一步鞏固公司在高成長、高利潤率的資料中心和航空航太市場的地位。管理層將有機銷售成長預期從8%上調至9-11%，預計2026年各業務部門利潤率將達到24.1-24.5%，營運每股收益為13.05-13.50美元。訂單成長動能強勁，美洲電氣業務訂單量有機成長 42%，總積壓訂單量也顯著擴大（電氣業務成長 48%，航空航太業務成長 28%）。我們認為，ETN 在計劃於 2027 年第一季完成行動出行業務分拆後，將受益於電氣化和數位化趨勢，以實現加速成長。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN